Ata uhi

An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Giuseppe Terrazzano (Author), Valentina Rubino (Author), Anna Teresa Palatucci (Author), Angela Giovazzino (Author), Flavia Carriero (Author), Giuseppina Ruggiero (Author)
Hōputu:	Pukapuka
I whakaputaina:	Frontiers Media S.A., 2020-05-01T00:00:00Z.
Ngā marau:	article
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment
mā: Giuseppe Ercolano, me ētahi atu.
I whakaputaina: (2019)

Superoxide Dismutase-1 Intracellular Content in T Lymphocytes Associates with Increased Regulatory T Cell Level in Multiple Sclerosis Subjects Undergoing Immune-Modulating Treatment
mā: Valentina Rubino, me ētahi atu.
I whakaputaina: (2021)

Insights on the Multifaceted Roles of Wild-Type and Mutated Superoxide Dismutase 1 in Amyotrophic Lateral Sclerosis Pathogenesis
mā: Valentina Rubino, me ētahi atu.
I whakaputaina: (2023)

mTOR in Human Diseases
mā: Dormond, Olivier
I whakaputaina: (2019)

Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway
mā: Xiangjin Zheng, me ētahi atu.
I whakaputaina: (2021)

mTOR Signaling in Metabolism and Cancer
I whakaputaina: (2020)

Roles of mTOR in Diabetic Kidney Disease
mā: Mako Yasuda-Yamahara, me ētahi atu.
I whakaputaina: (2021)

The role of mTOR in age-related diseases
mā: Zofia Chrienova, me ētahi atu.
I whakaputaina: (2021)

mTOR Inhibition and Tuberous Sclerosis Prevention
mā: J Gordon Millichap
I whakaputaina: (2013)

Promotion of colorectal cancer cell death by ezetimibe via mTOR signaling-dependent mitochondrial dysfunction
mā: Yuanyuan Zheng, me ētahi atu.
I whakaputaina: (2023)

Targeting PI3K/mTOR signaling in cancer
mā: Alexandre Arcaro
I whakaputaina: (2014)

Whey Protein e a sinalização de mTOR
mā: Marcos Roberto Campos de Macêdo
I whakaputaina: (2016)

Zastosowanie inhibitorów mTOR w wybranych schorzeniach dermatologicznych
mā: Karolina Osiecka, me ētahi atu.
I whakaputaina: (2011)

Modulation of the mTOR Pathway by Curcumin in the Heart of Septic Mice
mā: Bruna A. C. Rattis, me ētahi atu.
I whakaputaina: (2022)

The effect of eight weeks of high-intensity interval training on p-mTOR, T-mTOR and fibrosis of cardiac tissue and insulin resistance in diabetic male Wistar rats
mā: Saeed Dabagh Nikookheslat, me ētahi atu.
I whakaputaina: (2023)

Tetrandrine, an Activator of Autophagy, Induces Autophagic Cell Death via PKC-α Inhibition and mTOR-Dependent Mechanisms
mā: Vincent Kam Wai Wong, me ētahi atu.
I whakaputaina: (2017)

Qingfei Tongluo Mixture Attenuates Bleomycin-Induced Pulmonary Inflammation and Fibrosis through mTOR-Dependent Autophagy in Rats
mā: Shuyu Ge, me ētahi atu.
I whakaputaina: (2024)

Management of mTOR inhibitors oral mucositis: current state of knowledge
mā: Calvo Anne Sophie, me ētahi atu.
I whakaputaina: (2019)

Involvement of mTOR signaling in physiopathology and its potential therapeutic interventions
mā: Irene Martín-Bocanegra, me ētahi atu.
I whakaputaina: (2024)

The Mitochondrial Deubiquitinase USP30 Regulates AKT/mTOR Signaling
mā: Ruohan Zhang, me ētahi atu.
I whakaputaina: (2022)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
mā: Mathis Wehming, me ētahi atu.
I whakaputaina: (2023)

Exploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer
mā: Suhail Ahmad Mir, me ētahi atu.
I whakaputaina: (2023)

Role of nutrients and mTOR signaling in the regulation of pancreatic progenitors development
mā: Lynda Elghazi, me ētahi atu.
I whakaputaina: (2017)

Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition
mā: Aimin Yang, me ētahi atu.
I whakaputaina: (2015)

mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies
mā: Dániel Sztankovics, me ētahi atu.
I whakaputaina: (2024)

The Fate of the Tumor in the Hands of Microenvironment: Role of TAMs and mTOR Pathway
mā: Danilo Figueiredo Soave, me ētahi atu.
I whakaputaina: (2016)

mTOR signaling cascade in psoriatic disease: Double kinase mtor inhibitor a novel therapeutic target
mā: Smriti K Raychaudhuri, me ētahi atu.
I whakaputaina: (2014)

Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR
mā: Xiaojia Liu, me ētahi atu.
I whakaputaina: (2021)

Mediation of Anti-Keloid Effects of mTOR Inhibitors by Autophagy-Independent Machinery
mā: Meng Jiang, me ētahi atu.
I whakaputaina: (2021)

Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice
mā: Claudia Bürger, me ētahi atu.
I whakaputaina: (2017)

Intravenous route to choroidal neovascularization by macrophage-disguised nanocarriers for mTOR modulation
mā: Weiyi Xia, me ētahi atu.
I whakaputaina: (2022)

Effect of Puerarin Regulated mTOR Signaling Pathway in Experimental Liver Injury
mā: Bu-Gao Zhou, me ētahi atu.
I whakaputaina: (2018)

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
mā: Micol Silic-Benussi, me ētahi atu.
I whakaputaina: (2023)

Pharmacological mTOR inhibitors in ameliorating Alzheimer's disease: current review and perspectives
mā: Pei-Lun Xie, me ētahi atu.
I whakaputaina: (2024)

Glutamine Availability Regulates the Development of Aging Mediated by mTOR Signaling and Autophagy
mā: Jiao Zhou, me ētahi atu.
I whakaputaina: (2022)

Virtual Screening and Optimization of Novel mTOR Inhibitors for Radiosensitization of Hepatocellular Carcinoma
mā: Feng YQ, me ētahi atu.
I whakaputaina: (2020)

Inactivation of Minar2 in mice hyperactivates mTOR signaling and results in obesity
mā: Saran Lotfollahzadeh, me ētahi atu.
I whakaputaina: (2023)

mTOR Inhibitors in the complex treatment of high-risk vascular malformations in children
mā: I.M. Benzar, me ētahi atu.
I whakaputaina: (2020)

Place of mTOR inhibitors in management of BKV infection after kidney transplantation
mā: Thomas Jouve, me ētahi atu.
I whakaputaina: (2016)

Inflammatory-miR-301a circuitry drives mTOR and Stat3-dependent PSC activation in chronic pancreatitis and PanIN
mā: Fugui Li, me ētahi atu.
I whakaputaina: (2022)